Vivos Therapeutics’ mmRNA Oral Appliance Now Eligible for Medicare Reimbursement

Posted: January 27, 2022
Edited by Dentaltown staff

HIGHLANDS RANCH, Colo.—Vivos Therapeutics, a medical technology company focused on developing and commercializing diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring,  has received acceptance from a Centers for Medicare & Medicaid Services Pricing, Data Analysis and Coding (PDAC) contractor for its mmRNA (modified mandibular Repositioning Nighttime Appliance) device for treating mild to moderate OSA and snoring in adults. This acceptance places the mmRNA device on the PDAC list of oral appliances covered by and billable to Medicare. 
 
“This latest regulatory milestone opens the door for Vivos-trained dentists across the country to deliver our life-changing therapeutic technology to the millions of OSA sufferers in the U.S. who are either on Medicare or who have commercial medical insurance coverage that follows Medicare guidelines,” said Kirk Huntsman, Vivos CEO and chairman. “The latest data from our SleepImage home sleep apnea test screening shows that 47% of patients screened were positive for OSA, a far higher prevalence of OSA than has previously been assumed in the industry.”
 
Vivos’ oral appliances non-surgically address the dental tissue anomalies and malformations known to be associated with OSA. Patients treated with the Vivos System typically complete their therapy in 12 to 24 months, and in many cases, do not require further intervention.

For more information, visit vivoslife.com.
Views: 162
Sponsors
Townie Perks
Townie® Poll
Who or what do you turn to for most financial advice regarding your practice?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@farranmedia.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450